The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications

Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure with reduced ejection fract...

Descripción completa

Detalles Bibliográficos
Autores principales: Ráduly, Arnold Péter, Sárkány, Fruzsina, Kovács, Máté Balázs, Bernát, Brigitta, Juhász, Béla, Szilvássy, Zoltán, Porszász, Róbert, Horváth, Balázs, Szentandrássy, Norbert, Nánási, Péter, Csanádi, Zoltán, Édes, István, Tóth, Attila, Papp, Zoltán, Priksz, Dániel, Borbély, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820393/
https://www.ncbi.nlm.nih.gov/pubmed/36613900
http://dx.doi.org/10.3390/ijms24010446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820393/
https://www.ncbi.nlm.nih.gov/pubmed/36613900
http://dx.doi.org/10.3390/ijms24010446

Ejemplares similares